Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Mar 23, 2025

Keywords

ClinConnect Summary

Edoxaban, a factor Xa inhibitor, is used to prevent stroke or systemic thromboembolism (SSE) in patients with atrial fibrillation (AF). In elderly patients, the post-hoc analysis of the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial showed that a low-dose edoxaban regimen (LDER, 30 mg daily) reduced the risk of major bleeding compared to the standard-dose edoxaban regimen (SDER, 60 mg daily), without an offsetting increase in SSE risk. Furthermore, the Edoxaban Low-Dose for Elder Care Atrial ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age\>=80 years
• • Has been diagnosed atrial fibrillation
• • Has history of ischemic stroke or transient ischemic attack
• • Has any of the bleeding risk lists below
• • bodyweight \< 60 kg
• • creatinine clearance \< 50 mL/min
• • history of major bleeding or gastrointestinal bleeding
• • concurrent use of antiplatelet agents (such as aspirin, clopidogrel, ticagrelor, prasugrel, cilostazol), non-steroidal anti-inflammatory drugs, amiodarone, tacrolimus, cyclosporine, dronedarone.
• Exclusion Criteria:
• * Has ever used anticoagulants, defined as:
• • warfarin therapy within 1 month before study enrollment.
• • using heparin, low molecular weight heparin or direct oral anticoagulants within 7 days before study enrollment.
• • allergy to edoxaban
• • under regular dialysis, includes hemodialysis or peritoneal dialysis
• • refuse to provide informed consent.